Views & Analysis New NICE processes – same old problem? Following two recent controversial public consultations, NICE recently updated its Guide to the Processes of Technology Appraisal.
News NICE says 'no' to Roche's Perjeta after breast cancer surger... NICE consulting on first draft decision
News Patients call for end to two-year row over CF drug funding UK patients are stepping up efforts to resolve the “heartbreaking” row that is denying their families access to Vertex’s groundbreaking cystic fibrosis (CF) drug Orkambi, after Sweden becam
News J&J's Tremfya gets funding in Germany and UK Johnson & Johnson’s psoriasis drug Tremfya has been given the green light for funding by cost-effectiveness bodies in the UK and Germany.
Views & Analysis Who should pay for HTA? Part of the drive for strengthening EU cooperation on health technology assessment (HTA) is to tackle duplication of work
News Lung cancer drug Keytruda to become routinely available on N... NICE has given the green light for lung cancer drug Keytruda to be used as a routine treatment for certain patients in England.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
